Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort

A. Juergens, Rosalyn; Mariano, Caroline; Jolivet, Jacques; Finn, Nicholas; Rothenstein, J.; Neil Reaume, M.; Faghih, Amir; Labbé, Catherine; Owen, Scott; A. Shepherd, Frances; Villeneuve, J; Romeyer, F.; Pettersson, Filippa; Butts, Charles

doi:10.3747/co.25.4287

Public

Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort

Published in Current Oncology • Dec 1, 2018

Authors:

Rosalyn A. Juergens

Caroline Mariano

Jacques Jolivet

Abstract

Background: Nivolumab was the first immuno-oncology agent available for the treatment of lung cancer in Canada. In the present study, we evaluated the real-world benefit of nivolumab in Canadian patients with lung cancer. Methods: Patients included in the cohort were identified from a registry of pa...

Subject

Nivolumab

Medicine

Discontinuation

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!